

Proteases in cancer drug delivery

Jennifer Vandooren, Ghislain Opdenakker, Paul M. Loadman, Dylan R. Edwards

PII: S0169-409X(15)30026-0
DOI: doi: 10.1016/j.addr.2015.12.020
Reference: ADR 12906

To appear in: *Advanced Drug Delivery Reviews*

Received date: 29 October 2015
Revised date: 23 December 2015
Accepted date: 24 December 2015

Please cite this article as: Jennifer Vandooren, Ghislain Opdenakker, Paul M. Loadman, Dylan R. Edwards, Proteases in cancer drug delivery, *Advanced Drug Delivery Reviews* (2016), doi: 10.1016/j.addr.2015.12.020

Proteases in cancer drug delivery

Jennifer Vandooren[1], Ghislain Opdenakker[1], Paul M. Loadman[2], and Dylan R. Edwards[3,4]

Title for: Advanced Drug Delivery Reviews - special edition: **Extracellular Matrix (ECM) and ECM-like materials: Therapeutic Tools and Targets in Cancer Treatment**

[1] KU Leuven – University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Immunobiology, B-3000 Leuven, Belgium

[2]Institute of Cancer Therapeutics, School of Life Sciences, University of Bradford, Bradford, Yorkshire BD7 1DP, United Kingdom.

[3] School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK and

[4] The Genome Analysis Centre, Norwich Research Park, Norwich, NR4 7UH, UK.

Keywords: Prodrug; metalloproteinase; urokinase; legumain; cathepsin; nanoparticles

Address for correspondence: School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK;

email: dylan.edwards@uea.ac.uk

Abbreviations: ABP: Activity-Based Probe; ACPP: Activatable Cell-Penetrating Peptide; BD: Blocking Domain; ECM: Extracellular Matrix; MMP: Matrix Metalloproteinase; MMPI: MMP Inhibitor; NP: Nanoparticle; PAP: Protease-Activated Prodrug; PEG: Polyethylene glycol;